Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ofatumumab - Genmab/Novartis

Next Previous
X
Search
Drug Profile

Ofatumumab - Genmab/Novartis

Alternative Names: Anti-CD20 monoclonal antibody - Genmab; Arzerra; GSK-1841157; HuMax CD20; Kesimpta; OMB-157

Latest Information Update: 24 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Developer Genmab; GlaxoSmithKline; Mundipharma International; National Cancer Centre (Singapore); Novartis; Roswell Park Cancer Institute; University Health Network
  • Class Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Multiple sclerosis
  • Phase III B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase II Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Suspended Neuromyelitis optica
  • Discontinued Pemphigus vulgaris; Rheumatoid arthritis; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 14 Sep 2024 GlaxoSmithKline completes a phase II trial for Chronic lymphocytic leukaemia (First-line, combination therapy) in Sweden (IV, Infusion) (EudraCT number2010-024389-23)
  • 18 Apr 2024 Updated efficacy and adverse events data from a phase III trial in Multiple sclerosis released by Novartis
  • 13 Apr 2024 Interim adverse events data from the phase-III ALITHIOS trial in Multiple sclerosis presented at the 76th Annual Meeting of the American Academy of Neurology (AAN-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top